John H. Kehne

Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.

John H. Kehne, B M Baron, A A Carr et al. · Journal of Pharmacology and Experimental Therapeutics · 1996 · 359 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies.

S.M. Sorensen, John H. Kehne, Gina M. Fadayel et al. · Journal of Pharmacology and Experimental Therapeutics · 1993 · 256 citations

Medicine, Neuroscience, Pharmacology +17

Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine

Michael D. Lesem, Tram Tran-Johnson, Robert Riesenberg et al. · The British Journal of Psychiatry · 2011 · 153 citations · Full text

Medicine, Pharmacotherapy, Psychiatry +16

Effects of the Selective 5-HT2A Receptor Antagonist MDL 100,907 on MDMA-Induced Locomotor Stimulation in Rats

John H. Kehne · Neuropsychopharmacology · 1996 · 133 citations · Full text

Medicine, Neuroscience, Pharmacology +12

NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations

John H. Kehne, Timothy C. McCloskey, Bruce M. Baron et al. · European Journal of Pharmacology · 1991 · 128 citations

Medicine, Pharmacology, Behavioral Pharmacology +12